Valvular Disease News

 
 
  • Myxo Ring Dispute: Tale of Two Studies Puts IRB in Hot Seat The review board at the heart of the Myxo controversy seemingly had guidance in place that should have triggered FDA notification and patient consent before a study of the device went ahead.
  • AATS Higher-Volume Surgeons More Likely to Repair Than Replace MV To treat patients with moderate to severe mitral-valve regurgitation, surgeons who perform a high volume of mitral-valve surgeries are more likely to choose to repair rather than replace the valve, a study suggests.
  • AATS Mitral Valve-In-Valve Outcomes: Some Success, Some Concerns Results from the largest database of mitral valve-in-valve and mitral valve-in-ring procedures in high-risk patients with failed mitral-valve implants are mixed.
  • Grassley Investigation Unearths Second, Secret, Myxo Ring Study The US Senate Judiciary Committee ranking Republican has opened a fresh can of worms in the long-running Myxo annuloplasty ring controversy, this time hinting that Northwestern withheld key materials.
  • US District Court Issues Injunction Against CoreValve Sales US District Court judge issues a preliminary injunction against sales of Medtronic's CoreValve because it violates a patent held by Edwards Lifesciences.
  • ACC One-Year TAVR Mortality and Stroke Data Reassures Male gender, age, impaired renal function, the presence of COPD, higher STS scores, and non-transfemoral access were all associated with an increased risk of mortality, while female gender was associated with a higher risk of stroke.
  • Surgeons Pioneer Fully Endoscopic Aortic-Valve Replacement For years buzz has centered on transcatheter AV replacement; now surgeons in France are testing a fully endoscopic surgical approach that removes and replaces the native valve.
  • New Valve Guidelines Offer Staging, Risk-Scoring Advice The first new guidance on the diagnosis and treatment of valve disease in six years have been updated to include less invasive therapies, plus recommendations for gauging procedural risks.
  • Rethinking the High-Volumes/Best-Outcomes CV-Surgery Formula (Updated with interview) Accepted wisdom has CV surgeons and referring cardiologists relying on the "volume effect" for predicting in whose hands a patient needing CV surgery may fare the best. A new study looks further.
  • AHA Repair and Surgery Fare Equally Well in Ischemic MR (updated) Investigators testing repair vs replacement in patients with ischemic MR found no difference in left ventricular reverse remodeling or MACCE between the two approaches at 12 months.
  • TCT Solid Results for Repositionable TAVR Device A fully repositionable and retrievable percutaneous valve used in the treatment of patients with symptomatic and severe aortic stenosis significantly improves the mean aortic-valve pressure gradient.
  • TCT Low Strokes, PVL With CoreValve TAVR in Extreme Risk Trial The pivotal trial required for FDA approval of this device in nonsurgical, high-risk patients also met its primary end point of a significant reduction in all-cause mortality and stroke.
  • Alert FDA Approves MitraClip for Degenerative MR The US Food and Drug Administration has approved the MitraClip (Abbott Vascular) for patients with symptomatic degenerative mitral regurgitation deemed high risk for mitral valve surgery.
  • Early Surgery for Severe MR
  • AATS Valve-in-Valve Implantation Shows Positive Outcomes Results from use of the transcatheter valve-in-valve implantation in Nordic countries show few complications and low mortality rates.
  • SCAI VERITAS: Live Case Demos of TAVR Are Safe The FDA forbids the use of investigational transcatheter aortic-valve devices in live-case presentations being broadcast from US centers. A new study is offering some much-needed data into whether the agency's concerns are justified.
  • AATS Low-Dose Warfarin Seems Safe With Next-Gen Heart Valve Interim results show reduced risk of bleeding and no increased risk of thromboembolism when aortic-valve-replacement patients receive less aggressive anticoagulant therapy.
  • AATS AV Repair: Low Mortality, Durability In Younger Patients Five-year outcomes in patients with aortic regurgitation treated with surgical valve repair show few complications and low mortality, as well as device durability.
  • MitraClip (Abbott) at Four Years At four years, surgery for mitral-valve dysfunction was needed for one out of every five patients treated with the MitraClip compared with just 5.5% of patients who underwent surgery. These four-year results are in line with what was observed with the one-year data, say investigators.
  • Mitral Valve Disease in the Elderly: Repair or Replace? For elderly patients with mitral valve disease, surgery offers better survival than medical treatment, and repair seems better than replacement for most patients, a longitudinal analysis suggests.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.